CoChat

The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials

Open access
Liu, Yupeng, Ruan, Binye, Jiang, Huinan, Le, Siyu, Liu, Yi, Ao, Xuemei, Huang, Yufeng, Shi, Xudong, Xue, Ru, Fu, Xiaoyi, Wang, Shuran · 2023 · The American Journal of Clinical Nutrition
Cited by 110

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the treatment of obesity. OBJECTIVE To assess the weight-loss effects of GLP-1RAs in the treatment of patients with overweight or obesity without diabetes. METHODS This is a systematic review with meta-analysis and trial sequential analysis. PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from their inception to January 1, 2022. Eligible trials report on outcomes including body weight (BW), body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), or total body fat (TBF). Mean differences (MDs) and standardized mean differences (SMDs) were summarized using random-effects models. RESULTS Forty-one trials involving 15,135 participants were included. Compared with controls, GLP-1RAs significantly reduced BW (MD -5.319 kg, 95% CI: -6.465, -4.174), BMI (MD -2.373 kg/m2, 95% CI: -2.821, -1.924), WC (MD -4.302 cm, CI:-5.185 to -3.419), WHR (MD -0.011, CI -0.015 to -0.007), but not TBF (MD -0.320%, CI -1.420 to -0.780). Trial sequential analysis (TSA) supported conclusive evidence of the effects of GLP-1RAs on BW, BMI, and WC for weight loss. GLP-1RAs had nonlinear dose-response relationships with weight loss. Extensive sensitivity analyses demonstrated the robustness of the results, though the GRADE certainty of the evidence ranged from high to very low. High to moderate GRADE certainty of evidence suggested semaglutide as the most effective GLP-1RA agent, with the best efficacy and low to moderate risk of adverse effects. CONCLUSIONS The present study provides conclusive evidence for the effect of GLP-1RAs on weight loss in a nonlinear dose-response manner in patients with obesity or overweight without diabetes. In terms of changes in BW, BMI, and WC, there is firm evidence for the overall weight-loss effects of GLP-1RAs. Of the GLP-1RAs, semaglutide might be the most effective agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajcnut.2023.04.017

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 27

  1. Wild, 2006, ABC of obesity. Risk factors for diabetes and coronary heart disease, BMJ, 333, 1009, 10.1136/bmj.39024.568738.43 · DOI · Paper page
  2. Artham, 2009, Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss, Ochsner. J., 9, 124
  3. Alamuddin, 2016, Management of obesity, J. Clin. Oncol., 34, 4295, 10.1200/JCO.2016.66.8806 · DOI
  4. Cohen, 1992, A power primer, Psychol. Bull., 112, 155, 10.1037/0033-2909.112.1.155 · doi:10.1037/0033-2909.112.1.155 · Paper page
  5. Duval, 2000, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis, Biometrics, 56, 455, 10.1111/j.0006-341X.2000.00455.x · DOI · Paper page
  6. Thorlund, 2009, Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?, Int. J. Epidemiol., 38, 276, 10.1093/ije/dyn179 · DOI · Paper page
  7. Crippa, 2016, Multivariate dose-response meta-analysis: the dosresmeta R package, J. Stat. Softw., 72, 1
  8. Shim, 2019, Dose-response meta-analysis: application and practice using the R software, Epidemiol. Health., 41, 2019006, 10.4178/epih.e2019006 · DOI
  9. Wang, 2021, Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: a pilot trial, JGH Open, 5, 193, 10.1002/jgh3.12464 · DOI
  10. Weghuber, 2020, A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity, Pediatr. Obes., 15, 10.1111/ijpo.12624 · DOI · Paper page
  11. O'Neil, 2018, Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial, Lancet, 392, 637, 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
  12. Basolo, 2018, Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: a randomized, double-blind, placebo-controlled trial, Metabolism, 85, 116, 10.1016/j.metabol.2018.03.017 · DOI · Paper page
  13. Capristo, 2018, Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: a three-arm non-randomised, controlled, pilot study, Diabetes Metab, 44, 235, 10.1016/j.diabet.2017.12.007 · DOI · Paper page
  14. Liu, 2017, Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome, Clin. Endocrinol. (Oxf)., 87, 767, 10.1111/cen.13454 · DOI
  15. Nylander, 2017, Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial, Reprod. Biomed. Online., 35, 121, 10.1016/j.rbmo.2017.03.023 · DOI · Paper page
  16. Ishøy, 2017, Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial, Diabetes Obes. Metab., 19, 162, 10.1111/dom.12795 · DOI · Paper page
  17. Robert, 2015, Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - a pilot study, Obes. Res. Clin Pract., 9, 301, 10.1016/j.orcp.2015.03.005 · DOI
  18. Faurschou, 2015, Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial, J. Eur. Acad. Dermatol. Venereol., 29, 555, 10.1111/jdv.12629 · DOI
  19. Ariel, 2014, Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes, Nutr. Metab. Cardiovasc. Dis., 24, 1317, 10.1016/j.numecd.2014.06.010 · DOI
  20. Jensterle Sever, 2014, Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin, Eur. J. Endocrinol., 170, 451, 10.1530/EJE-13-0797 · DOI · Paper page
  21. Kim, 2013, Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes, Diabetes Care, 36, 3276, 10.2337/dc13-0354 · DOI
  22. Kelly, 2013, The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial, JAMA Pediatr, 167, 355, 10.1001/jamapediatrics.2013.1045 · DOI · Paper page
  23. Kelly, 2012, Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study, Obesity (Silver Spring), 20, 364, 10.1038/oby.2011.337 · DOI · Paper page
  24. Dushay, 2012, Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes, Diabetes Care, 35, 4, 10.2337/dc11-0931 · DOI
  25. Rosenstock, 2010, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes, Diabetes Care, 33, 1173, 10.2337/dc09-1203 · DOI · Paper page
  26. Verdich, 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans, J. Clin. Endocrinol. Metab., 86, 438
  27. Kao, 2018, Inclusion of fructooligosaccharide and resistant maltodextrin in high fat diets promotes simultaneous improvements on body fat reduction and fecal parameters, Molecules, 23, 2169, 10.3390/molecules23092169 · DOI

Cited by

See all 110

Metadata

Authors
Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., & Wang, S.
Venue
The American Journal of Clinical Nutrition
Publisher
Elsevier BV
Published
2023-09
Volume
118
Issue
3
Pages
614-626
ISSN
0002-9165 (ISSN-L)
OpenAlex
W4385659664
Cited by
110
References
38
FWCI
6.59
Type
journal article
Language
en
Open access
bronze
Licence
Funders
Wenzhou Medical University (89219029)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1016/j.ajcnut.2023.04.017
The paper
Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., & Wang, S. (2023). The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. The American Journal of Clinical Nutrition. https://doi.org/10.1016/j.ajcnut.2023.04.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.